# US 2016/0354462 A1 · Vaccine and Therapeutic Delivery System

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354462 A1
- Document ID: US20160354462A1
- Status: Published application
- Kind: A1
- Application number: 15/172,947
- Filed: 2016-06-03
- Published: 2016-12-08
- Earliest claimed: 2011-09-23
- Assignees: Forsyth Dental Infirmary for Children
- Applicants: Forsyth Dental Infirmary for Children
- Inventors: Antonio Campos-Neto; Mark Cayabyab; Margaret Duncan
- Web page: https://patentgrep.com/patent/US20160354462A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/005: from viruses
- C07K 14/155: Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K 14/162: {env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site}
- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- C07K 14/35: from Mycobacteriaceae (F)
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/2457: {Pullulanase (3.2.1.41)}
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N 15/746: {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}
- C12Y 302/01041: Pullulanase (3.2.1.41)
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/572: {cytotoxic response}
- C07K 2319/02: containing a signal sequence
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N 2740/15022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/15033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2740/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16051: Methods of production or purification of viral material
- C12N 2740/16071: Demonstrated in vivo effect
- C12N 2740/16111: concerning HIV env
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16171: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.

## Claims

### Claim 1

An integrally transformed non-pathogenic, commensal bacterium that can express a nucleic acid molecule of a foreign polypeptide therein, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacterium, wherein the bacterium is Streptococcus mitis.

### Claim 2 (depends on 1)

The integrally transformed non-pathogenic, commensal bacterium of claim 1, wherein the nucleic acid molecule of the foreign polypeptide comprises an antigen that elicits an immunogenic response in the individual, a vaccine antigen, an inhibitor of a pathogen, an immune booster, a modulator, a composition used in the treatment of a disease or condition, or a combination thereof.

### Claim 3 (depends on 2)

The integrally transformed non-pathogenic, commensal bacterium of claim 2, wherein the vaccine antigen is selected from the group consisting of M. leprae antigens, M. tuberculosis antigens, M. africanum antigens, M. intracellulare antigens, M. avium antigens, and human immunodeficiency virus antigens.

### Claim 4 (depends on 2)

The integrally transformed non-pathogenic, commensal bacterium of claim 2, wherein an inhibitor of a pathogen is a small, antimicrobial peptide that can have an effect against various pathogens selected from the group consisting of: M. leprae, M. tuberculosis, M. africanum, M. intracellulare, M. avium, and human immunodeficiency virus types I and II.

### Claim 5 (depends on 2)

The integrally transformed non-pathogenic, commensal bacterium of claim 2, wherein the immune booster and modulator is selected from the group consisting of: interleukins, interferons, and cytokines such as IL-1, IL-2, IL-4, IL-6, IL-8, IL12, IL-17, IL-2 IL-21 and IL-22 and cytokines GMCSF, MCSF, MIP1alpha and beta, TNFalpha and beta, IFNalpha and beta and TGFbeta.

### Claim 6 (depends on 1)

The integrally transformed non-pathogenic, commensal bacterium of claim 1, wherein the nucleic acid molecule coding for a foreign polypeptide that is expressed in the cytoplasm, in the cell membrane or cell wall or exports to the cell surface of the bacterium.

### Claim 7 (depends on 3)

The integrally transformed non-pathogenic, commensal bacterium of claim 3, wherein the non-pathogenic, commensal bacterium comprises S. mitis and the gene that expresses or secretes a polypeptide on the cell surface of the bacterium is selected from the group consisting of: serine-rich GspB homologue or the pullulanase polypeptide.

### Claim 8 (depends on 2)

The integrally transformed non-pathogenic, commensal bacterium of claim 2, wherein the foreign polypeptide comprises a HIV vaccine or a tuberculosis vaccine.

### Claim 9 (depends on 8)

The integrally transformed non-pathogenic, commensal bacterium of claim 8, wherein the HIV antigen is gp120 env, gp140 env, gp160 env, gag, pol, nef, vif, vpr, vpu, tat, rev, nef or HIV T20 polypeptide inhibitor.

### Claim 10 (depends on 9)

The integrally transformed non-pathogenic, commensal bacterium of claim 9, wherein the nucleic acid molecule that encodes the HIV T20 polypeptide has a sequence comprising SEQ ID NO: 49.

### Claim 11 (depends on 10)

The integrally transformed non-pathogenic, commensal bacterium of claim 10, wherein the HIV T20 polypeptide has a sequence comprising SEQ ID NO: 50.

### Claim 12 (depends on 7)

The integrally transformed non-pathogenic, commensal bacterium of claim 7, wherein a nucleic acid molecule that encodes HIV T20 is inserted into a gene that expresses or secretes a pullulanase polypeptide, to thereby obtain a gene that expresses or secretes an HIV gp120/pullulanase fusion protein.

### Claim 13 (depends on 9)

The integrally transformed non-pathogenic, commensal bacterium of claim 9, the nucleic acid molecule of the HIV T20/pullulanase fusion protein has a sequence that comprises SEQ ID NO: 79.

### Claim 14 (depends on 9)

The integrally transformed non-pathogenic, commensal bacterium of claim 9 expresses the HIV T20/pullulanase fusion protein has a sequence that comprises SEQ ID NO: 80.

### Claim 15 (depends on 4)

The integrally transformed non-pathogenic, commensal bacterium of claim 4, wherein the M. tuberculosis antigen has a polypeptide sequence is selected from the group consisting of:
a) an amino acid sequence encoded by a nucleic acid molecule of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, or combination thereof;
b) an amino acid sequence encoded by a coding region of a nucleic acid molecule of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, or combination thereof;
c) an amino acid sequence encoded by a complement of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, or combination thereof;
d) an amino acid sequence encoded by a nucleic acid molecule that hybridizes to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, or combination thereof under high stringency conditions, wherein said conditions comprise 1×SSC, 1% SDS and 0.1-2 mg/ml denatured calf thymus DNA at 65° C.; or
e) an amino acid sequence set forth in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48 or combination thereof.

### Claim 16 (depends on 4)

The integrally transformed non-pathogenic, commensal bacterium of claim 4, wherein the M. tuberculosis antigen is encoded by a nucleic acid sequence is selected from the group consisting of:
a) SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, or combination thereof;
b) the coding region of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, or combination thereof;
c) a complement of SEQ ID NO 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, or combination thereof;
d) a sequence that hybridizes to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, or combination thereof; and
e) a sequence that encodes SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, or combination thereof.

### Claim 17 (depends on 1)

A polypeptide expressed by the integrally transformed non-pathogenic, commensal bacteria of claim 1.

### Claim 18 (depends on 1)

A method of delivering a foreign protein to an individual to induce mucosal immunity, the method comprises: contacting the integrally transformed non-pathogenic, commensal bacteria of claim 1 with tissue of the oral cavity or upper respiratory tract of the individual in an amount sufficient for colonization of said bacteria.

### Claim 19 (depends on 18)

The method of claim 18, wherein the amount of the integrally transformed bacteria that is contacted with the oral cavity or upper respiratory tract ranges between about 1×103 and about 1×1010.

### Claim 20 (depends on 19)

The method of claim 19, further comprising subjecting the individual to an antibiotic prior to contacting the integrally transformed non-pathogenic, commensal bacteria with the individual.
